Pricing
  1. US-listed companies
  2. Regenicin, Inc.
  3. Financials
  4. Common stock and paid-in capital

Regenicin, Inc.【RGIN】

Market cap
$15.35K
P/E ratio
SummaryFinancials
Period EndCommon stock and paid-in capital (Million USD)YoY (%)
Sep 30, 202110+0.00%
Sep 30, 202010+0.00%
Sep 30, 201910+0.30%
Sep 30, 201810+0.00%
Sep 30, 201710+0.00%
Sep 30, 201610+0.66%
Sep 30, 201510+13.61%
Sep 30, 20149+4.82%
Sep 30, 20139+17.00%
Sep 30, 20127+10.61%
Sep 30, 20117

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)